It does not constitute prescribing guidance and should not be used to self-administer or source this medicine outside of an approved clinical trial
That means you cannot legitimately place 10.8% for cagrilintide next to 24.2% for retatrutide and declare a winner, because those numbers come from different trials, different populations, different durations (26 vs 48 weeks), different doses, and critically a monotherapy figure for one versus a monotherapy figure for the other, while cagrilintides strongest data are actually as a combination
Consult your provider if fatigue is severe, worsening, or does not improve after addressing nutrition and hydration
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
The guideline also says the plan should be decided with a doctor or licensed clinician, with side effects and the risk of weight regain after stopping kept in view